Current Report Filing (8-k)
August 12 2020 - 07:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 12,
2020
Edesa Biotech, Inc.
(Exact Name of Registrant as Specified in its Charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
|
(Address
of Principal Executive Offices)
|
(289) 800-9600
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
Common
Shares
|
|
EDSA
|
|
The Nasdaq Stock Market
LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item
2.02
Results of Operations and Financial Condition.
On
August 12, 2020, Edesa Biotech, Inc. (the “Company”)
issued a press release announcing its financial results for the
three and nine-month period ended June 30, 2020 (the
“Earnings Release”). The full text of the Earnings
Release is attached hereto as Exhibit 99.1. The information
furnished herein and therein shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that Section, or incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.
Item
9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press
release issued by Edesa Biotech, Inc. dated August 12,
2020.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Edesa
Biotech, Inc.
|
|
|
|
Date:
August 12, 2020
|
By:
|
/s/
Kathi Niffenegger
|
|
Name:
|
Kathi
Niffenegger
|
|
Title:
|
Chief
Financial Officer
|
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Mar 2023 to Mar 2024